Background
==========

Interleukin-2 (IL-2) has been extensively used as a single agent for anti-cancer immunotherapy \[[@B1],[@B2]\]. This immune modulatory cytokine can induce long term cures and has been approved by the Food and Drug Administration for standard therapy of metastatic melanoma and renal cell cancer. In addition, it appears that systemic IL-2 administration may increase the frequency of tumor regressions mediated by tumor antigen-specific immunization \[[@B3]\]

Although, it has been postulated that IL-2 acts through the *in vivo*expansion and activation of cytotoxic T lymphocytes \[[@B1]\] and/or the promotion of their migration within target tissues \[[@B3]\], it is likely that at the pharmacologic doses used therapeutically IL-2 has broader immune/pro-inflammatory effects \[[@B4],[@B5]\]. Thus, the mechanism(s) through which systemic IL-2 administration mediates cancer regression remains unknown. It is also unknown whether the substantial toxicity associated with IL-2 administration (that limits its therapeutic usefulness) \[[@B6]\] is mediated through pathways common or distinct from those mediating its anti-cancer effects \[[@B7]\]. It has been observed that hematological toxicity induced by IL-2 (thrombocytopenia and lymphopenia) is associated with increased frequency of clinical responses \[[@B8]\]. In addition, reversal of IL-2-induced toxicity by corticosteroid or anti-TNF-α antibodies blunts its therapeutic effects suggesting a proinflammatory nature for this association \[[@B9],[@B10]\]. Yet, these and other associations between therapeutic and toxic effects are weak and inconclusive and in all probability different pathways may mediate the two phenomena. Obviously, the ability to segregate the anti-cancer effects of IL-2 in target tissues from its systemic toxic effects may be central for the development of improved anti-cancer therapies \[[@B11]\].

We have recently analyzed changes induced by the systemic administration of IL-2 on the transcriptional profile of circulating mononuclear cells and melanoma metastases \[[@B12]\]. This was done by comparing samples obtained before therapy and three hours after IL-2 administration, a time point found to be most informative based on preliminary time course studies. Samples were serially obtained through blood draws and fine needle aspirates of melanoma metastases following a previously validated RNA amplification procedure \[[@B13]\]. This study suggested that the systemic effects of IL-2 administration diverged from those identifiable within the tumor microenvironment since in the latter they seemed primarily restricted to the activation of mononuclear phagocytes. In fact, systemic IL-2 administration had very little direct effects on lymphocyte activation or migration to the tumor site, nor had direct effects on the survival of tumor cells. More specifically, it appeared that IL-2 induced activation of resident mononuclear phagocytes into mature antigen presenting cells. In addition IL-2 induced activation of cytolytic mechanisms and a massive production of chemo-attractants that could secondarily recruit other immune cells. In addition, the hypothesis that the direct or indirect effects of IL-2 in the target organ are mediated through mononuclear phagocyte activation is in line with the recently reported observation that macrophage activation by IL-2 is essential for tumor regression \[[@B14]\].

*In vitro*testing failed to identify IL-2 as the direct agonist responsible for the activation of mononuclear macrophages (unpublished observation) suggesting that a down-stream cascade of immune modulators produced by IL-2-responsive cells *in vivo*might be the principal mediator of the effect of this cytokine on the tumor microenvironment. Since it is unlikely that IL-2 directly mediates all of the effects observed after its systemic administration, we hypothesized that the changes in the transcriptional program of melanoma metastases were most likely resulting from an array of soluble factors secondarily produced by IL-2 receptor-bearing immune cells. Indeed, a preliminary *in vitro*analysis of supernatants from cultures of circulating mononuclear cells exposed to IL-2 revealed an intense production of a broad array of cytokines and other soluble factors \[[@B15]\].

The cytokine cascade or cytokine storm induced by systemic IL-2 administration has been extensively reported in the past and attempts have been made to associate individual parameters with biological effects \[16,-19\]. However, these studies were limited by the number of cytokines tested whose selection was based on an educated guess of their relevance to immune modulation. Recent advances in high-throughput analysis of gene and protein expression allow, however, a global and unbiased overview of complex biological processes adding novel dimensions to the study of this problem. Here we studied the serum levels of 68 soluble factors including cytokines, chemokines, growth factors, soluble receptors and metalloproteinases in patients with RCC undergoing systemic IL-2 therapy. The 68 soluble factors were assembled in a protein array platform (Searchlight™, Boston, MA) without predetermined bias except for their known or suspected relevance to immune phenomena. This was done with two main purposes: the first was to attain a general estimate of the ratio of biologically active factors induced by systemic IL-2 administration out of a pool of randomly chosen reagents. This parameter yields a rough estimate of the complexity and lack of specificity of systemic IL-2 treatment. The second was to provide a map of cytokine secretion patterns relevant to clinical IL-2 administration that could help forecast its toxic or beneficial effects in future prospective studies.

The results suggested that 1) the serum concentration of more than half the soluble factors studied changed significantly during therapy; 2) changes became more dramatic with increasing doses; 3) subclasses of soluble factors displayed different kinetics and 4) cytokine patterns varied quantitatively among patients.

Results and Discussion
======================

Serum was collected from 16 patients (Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}). From 15 patients, samples could be obtained before treatment and 3 hours after the 1^st^dose. However, in only 10 patients could the pre-determined collection be completed by obtaining serum before therapy and 3 hours after the 1^st^and 4^th^dose of IL-2. Time points of serum collection were selected based on previous experience suggesting incremental effects of IL-2 administration with increasing doses \[[@B12]\]. It was felt the four doses represented a reasonable midpoint of IL-2 therapy that could be achieved in most patients before interruption of treatment due to limiting toxicity. Serum collections were obtained 3 hours after IL-2 administration because it is around this time that most of the systemic signs of IL-2 administration are apparent suggesting that the highest levels of soluble factors are reached around that time point. Serum was immediately separated to avoid protein degradation and stored frozen. All serum samples were thawed simultaneously at the completion of the study and immediately tested for the presence of 68 soluble factors (including chemokines, cytokines, soluble cytokine receptors and cell surface molecules) using Searchlight™ arrays.

###### 

Characteristics of the patients enrolled in the study

  **Patient \#**   **Sampling: pre, post dose\#**   **Course/ Cycle of Sampling**   **Response**     **Biological Response**   **\# of doses**
  ---------------- -------------------------------- ------------------------------- ---------------- ------------------------- -----------------
  p1               pre, post 1                      c1c2                            SD 2C            NR                        3
  p2               pre, post 1, post 4              c3c1                            SD 2C            NR                        8
  p3               pre, post 1, post 5              c3c1                            PR 1C CR 3C      BR                        5
  p4               pre, post 1, post 4              c2c1                            PR 1C SD 2C PD   BR                        7
  p5               pre, post 1, post 4              c1c2                            SD 1C PD 2C      NR                        6
  p6               pre, post 1                      c1c2                            PR 2C PD 3C      BR                        4
  p7               pre, post 1                      c2c1                            SD 1C            NR                        4
  p8               pre                              c1c1                            PD 1C            NR                        8
  p9               pre, post 1, post 4              c1c1                            PD 1C            NR                        7
  p10              pre, post 1                      c1c2                            MR 1C            BR                        7
  p11              pre, post 1                      c3c2                            SD 1C PR 3C      NR                        3
  p12              pre, post 1, post 4              c1c1                            SD               NR                        8
  p13              pre, post 1, post 4              c1c1                            PD 1C            NR                        7
  p14              pre, post 1, post 4              c2c1                            MR 1C            BR                        8
  p15              pre, post 1, post 4              c1c1                            MR 1C            BR                        7
  p16              pre, post 1, post 4              c1c1                            PD               NR                        9

C = course; CR = complete response; SD = stable disease; PR = partial response; MR = mixed response; PD = progressive disease; BR Biological response = CR+PR+MR; NR = Non responder = PD+SD

###### 

Toxicity evaluation in the 16 patients with RCC enrolled in this study

  **Patient \#**   **Age yr**   **Doses**   **Hemoglobin**   **WBC count**   **Platelet Count**   **Bilirubin**   **SGOT**   **Creatinine**
  ---------------- ------------ ----------- ---------------- --------------- -------------------- --------------- ---------- ----------------
  p1               41           3           grade 2          \*              \*                   \*              \*         \*
  p2               56           8           \*               \*              grade 1              \*              \*         \*
  p3               53           5           grade 1          \*              \*                   \*              \*         \*
  p4               54           7           \*               \*              grade 1              grade 1         grade 1    grade 1
  p5               58           6           grade 2          grade 2         grade 2              grade 3         grade 1    grade 3
  p6               47           4           grade 1          \*              \*                   \*              \*         \*
  p7               54           4           \*               \*              \*                   \*              \*         grade 2
  p8               41           8           grade 1          \*              \*                   grade 2         grade 1    \*
  p9               44           7           \*               \*              \*                   \*              grade 1    \*
  p10              36           7           \*               \*              \*                   \*              \*         \*
  p11              60           3           \*               \*              \*                   \*              \*         \*
  p12              45           8           \*               \*              grade 1              \*              grade 1    grade 2
  p13              70           7           \*               \*              \*                   grade 1         grade 1    \*
  p14              36           8           \*               grade 1         grade 3              \*              \*         \*
  p15              66           7           \*               \*              \*                   \*              grade 3    \*
  p16              56           9           \*               \*              \*                   \*              grade 2    \*

Toxicity grade is based on the CMC common toxicity criteria

Cytokines whose concentration in the present conditions was consistently below the threshold of detection of the assay (LIF, IFNα, GM-CSF, IL-1α, IL-1β, IL-9, IL-12p70, IL-13) were excluded from the analysis because we could not rule out that significant changes may have occurred with treatment that could not be detected due to the limit of the assay sensitivity. In addition, we excluded IL-2 because it was impossible to distinguish the endogenous levels produced by IL-2 stimulated cells from the circulating exogenously administered recombinant IL-2. The serum concentration of 61 % of evaluable factors changed significantly after one dose of IL-2 (36/59) (Table [3](#T3){ref-type="table"}). Similarly, 56 % of the evaluable soluble factors (33/59) increased significantly in concentration after 1 dose of IL-2 in the 10 patients who completed the study (Table [4](#T4){ref-type="table"}). After four doses, the concentration of the majority of soluble factors studied (76%; 45/59) increased significantly (Table [5](#T5){ref-type="table"}). Interestingly, the serum level of 59 % (35/59) of the evaluable soluble factors changes significantly between the 1^st^and after 4^th^dose (Table [6](#T6){ref-type="table"}). While the serum levels of most soluble factors increased progressively during the 24 hours that spanned between the first and the fourth dose a smaller group including MCP-2, MIP-1β, MCP-1, NAP-2, IL-6R and Rantes decreased in concentration between the first and the fourth dose. Two factors, MMP-3 and Exodus-2 decreased 3 hours after the first dose but increased noticeably after the 4^th^. Although the results presented in this study are exploratory and fewer cytokine changes maintained significance after correcting the p~2~-value for the number of tests according to Bonferroni\'s method \[[@B20]\], it is likely that the changes observed are representative of true biological behavior of these factors in response to systemic IL-2 administration and a more powerful study will confirm these results by allowing a higher level of significance.

###### 

Soluble factor (pg/ml) concentrations in the serum of 15 patients enrolled in the study (only factors that demonstrated significant changes in concentration after the 1^st^dose compared with before therapy are shown)

  **Soluble Factor**   **Average before IL-2**   **STD error before**   **Average after 1 dose**   **STD error after 1 dose**   **p value before vs. after I dose**   **Bonferroni correction**
  -------------------- ------------------------- ---------------------- -------------------------- ---------------------------- ------------------------------------- ---------------------------
  **IL2\***            0                         0                      3269                       841                          0.00126                               0.07409
  **TNFR2**            3197                      222                    6215                       462                          0.00000                               0.00001
  **MMP9**             246408                    29501                  764715                     53413                        0.00000                               0.00008
  **TNFR1**            1659                      92                     5217                       568                          0.00000                               0.00024
  **IFNγ**             152                       17                     235                        19                           0.00000                               0.00027
  **IP10**             152                       13                     2006                       267                          0.00001                               0.00030
  **MIP3b**            151                       12                     421                        45                           0.00001                               0.00040
  **MCP2**             36                        6                      1776                       261                          0.00001                               0.00045
  **MIP1b**            525                       137                    35905                      5761                         0.00002                               0.00100
  **MMP8**             1502                      321                    3977                       537                          0.00002                               0.00109
  **SDF1b**            75                        16                     836                        137                          0.00005                               0.00322
  **Lymph**            142                       20                     338                        43                           0.00007                               0.00407
  **IL7**              3                         1                      10                         2                            0.00008                               0.00477
  **IL5**              1                         1                      9                          2                            0.00012                               0.00691
  **MCP3**             12                        1                      23                         3                            0.00020                               0.01172
  **I309**             22                        4                      73                         12                           0.00026                               0.01547
  **E-Selectin**       111526                    5901                   127683                     5461                         0.00030                               0.01753
  **IL15**             1                         1                      6                          1                            0.00038                               0.02261
  **Eotaxin**          130                       16                     401                        65                           0.00047                               0.02757
  **ITAC**             31                        3                      139                        25                           0.00056                               0.03314
  **MIP1a**            3000                      111                    3228                       104                          0.00102                               0.06033
  **Gro-A**            297                       95                     1848                       388                          0.00104                               0.06121
  **Angio2**           467                       58                     671                        71                           0.00107                               0.06330
  **IL6**              61                        13                     1092                       265                          0.00112                               0.06589
  **VegF**             1112                      139                    1498                       132                          0.00130                               0.07661
  **MCP1**             1327                      248                    124449                     32058                        0.00136                               0.08025
  **MIG**              262                       35                     933                        178                          0.00262                               0.15480
  **IL8**              65                        4                      800                        211                          0.00278                               0.16379
  **IL4**              0                         0                      4                          1                            0.00422                               0.24896
  **TNFa**             539                       48                     640                        50                           0.00719                               0.42432
  **TARC**             282                       47                     520                        88                           0.00939                               0.55398
  **MIP3a**            17                        3                      827                        291                          0.01195                               0.70484
  **IL6R**             24605                     1759                   27935                      2652                         0.01393                               0.82204
  **IL10**             2                         1                      41                         15                           0.01517                               0.89505
  **MDC**              605                       77                     661                        74                           0.03338                               1.96915
  **MMP10**            1440                      148                    1645                       147                          0.04876                               2.87674
  **MMP1**             13937                     1775                   16437                      1602                         0.05007                               2.95398

Soluble Factors (pg/ml) present in the serum of patients undergoing high dose IL-2 immunotherapy were averaged before and after 1 dose of IL-2. A paired 2-tailed student *t*test was used to assess significance with an arbitrary cutoff of p= 0.05. Bonferroni\'s correction was applied to the data set by correcting for a total of 59 soluble factors (IL-2 was not factored in); IL-2 levels were included as internal control (\*) since these values reflect in part administered human recombinant IL-2.

###### 

Soluble factor (pg/ml) concentrations in the serum of 10 patients who completed the study (only factors that demonstrated significant changes in concentration after the 1^st^dose compared with before therapy are shown)

  **Soluble Factor**   **Average before IL-2**   **STD error before IL-2**   **Average after 1 dose**   **STD error after 1 dose**   **p value before vs. after 1 dose**   **Bonferroni Correction**
  -------------------- ------------------------- --------------------------- -------------------------- ---------------------------- ------------------------------------- ---------------------------
  **IL2\***            0                         0                           3668                       1178                         0.00948                               0.55953
  **TNFR1**            1641                      112                         4702                       512                          0.00005                               0.00292
  **MMP8**             1187                      455                         3340                       500                          0.00008                               0.00486
  **TNFR2**            3195                      259                         6014                       628                          0.00010                               0.00588
  **MCP1**             984                       227                         81270                      13486                        0.00013                               0.00787
  **IP10**             146                       18                          1571                       273                          0.00047                               0.02778
  **MCP2**             32                        9                           1500                       291                          0.00050                               0.02950
  **MMP9**             233004                    43617                       736428                     76301                        0.00051                               0.02984
  **I309**             18                        4                           52                         8                            0.00057                               0.03372
  **IFNγ**             149                       21                          222                        25                           0.00059                               0.03477
  **IL5**              0                         0                           8                          2                            0.00094                               0.05563
  **MIP1b**            512                       205                         30149                      6560                         0.00097                               0.05714
  **MIP3b**            142                       17                          347                        51                           0.00108                               0.06345
  **VegF**             865                       131                         1392                       181                          0.00175                               0.10307
  **IL7**              2                         1                           10                         2                            0.00228                               0.13444
  **IL15**             0                         0                           6                          2                            0.00302                               0.17834
  **E-Selectin**       106029                    5703                        118981                     5972                         0.00351                               0.20688
  **SDF1b**            62                        21                          646                        154                          0.00372                               0.21974
  **Lymph**            111                       22                          259                        39                           0.00400                               0.23580
  **IL6**              50                        5                           747                        201                          0.00521                               0.30754
  **MCP3**             10                        1                           17                         2                            0.00616                               0.36333
  **MMP1**             12912                     2478                        17411                      2235                         0.00686                               0.40490
  **Eotaxin**          115                       22                          318                        65                           0.00762                               0.44948
  **MIP1a**            2952                      143                         3215                       141                          0.00790                               0.46638
  **Angio2**           494                       78                          655                        101                          0.01068                               0.63039
  **MCP4**             84                        19                          264                        71                           0.01082                               0.63834
  **ITAC**             29                        4                           110                        26                           0.01104                               0.65159
  **TARC**             248                       59                          478                        112                          0.02152                               1.26942
  **IL8**              61                        4                           456                        151                          0.02259                               1.33290
  **IL4**              0                         0                           5                          2                            0.02601                               1.53464
  **TNFa**             521                       65                          610                        59                           0.02824                               1.66587
  **Gro-A**            314                       146                         1401                       468                          0.03637                               2.14567
  **TIMP2**            75277                     5629                        85674                      4973                         0.04508                               2.65947
  **KGF**              373                       117                         470                        97                           0.04513                               2.66289

Soluble Factors (pg/ml) present in the serum of patients undergoing high dose IL-2 immunotherapy were averaged before and after 1 dose of IL-2. A paired 2-tailed student *t*test was used to assess significance with an arbitrary cutoff of p= 0.05. Bonferroni\'s correction was applied to the data set by correcting for a total of 59 soluble factors (IL-2 was not factored in); IL-2 levels were included as internal control (\*) since these values reflect in part administered human recombinant IL-2.

###### 

Soluble factor (pg/ml) concentrations in the serum of 10 patients who completed the study (only factors that demonstrated significant changes in concentration after the 4^th^dose compared with before therapy are shown)

  **Soluble Factor**   **Average before IL-2**   **STD error before IL-2**   **Average after 4 doses**   **STD error after 4 doses**   **p value before vs. after 4 doses**   **Bonferroni correction**
  -------------------- ------------------------- --------------------------- --------------------------- ----------------------------- -------------------------------------- ---------------------------
  **IL2\***            0                         0                           1426                        394                           0.00410                                0.24205
  **MCP2**             32                        9                           296                         34                            0.00001                                0.00047
  **I309**             18                        4                           222                         25                            0.00001                                0.00070
  **IP10**             146                       18                          2940                        390                           0.00003                                0.00178
  **VegF**             865                       131                         1411                        132                           0.00003                                0.00191
  **ITAC**             29                        4                           438                         57                            0.00003                                0.00200
  **TNFR1**            1641                      112                         6067                        651                           0.00004                                0.00207
  **IFNγ**             149                       21                          246                         16                            0.00004                                0.00234
  **IL15**             0                         0                           14                          2                             0.00005                                0.00269
  **MCP1**             984                       227                         31267                       4583                          0.00006                                0.00367
  **MIP3b**            142                       17                          33836                       5140                          0.00007                                0.00405
  **Lymph**            111                       22                          639                         95                            0.00010                                0.00571
  **E-Selectin**       106029                    5703                        377934                      40503                         0.00011                                0.00638
  **TARC**             248                       59                          8993                        1517                          0.00015                                0.00867
  **SDF1b**            62                        21                          883                         142                           0.00018                                0.01045
  **MMP8**             1187                      455                         5081                        927                           0.00024                                0.01406
  **MCP3**             10                        1                           53                          8                             0.00029                                0.01685
  **MDC**              586                       111                         1272                        214                           0.00031                                0.01841
  **Eotaxin**          115                       22                          392                         67                            0.00032                                0.01890
  **TIMP2**            75277                     5629                        108359                      4266                          0.00033                                0.01949
  **Exodus2**          419                       71                          1108                        157                           0.00049                                0.02911
  **MMP13**            839                       221                         1742                        171                           0.00055                                0.03224
  **TIMP1**            198383                    20136                       1021646                     178036                        0.00071                                0.04194
  **TNFa**             521                       65                          839                         74                            0.00086                                0.05090
  **MIP1b**            512                       205                         4072                        794                           0.00105                                0.06189
  **TNFR2**            3195                      259                         16353                       3113                          0.00115                                0.06774
  **HGF**              8281                      2359                        17298                       1311                          0.00251                                0.14822
  **IL5**              0                         0                           40                          10                            0.00274                                0.16167
  **MMP9**             233004                    43617                       657077                      142793                        0.00391                                0.23066
  **IL7**              2                         1                           6                           2                             0.00508                                0.29968
  **MMP2**             210099                    37913                       399516                      50101                         0.00510                                0.30111
  **MMP10**            1467                      220                         3247                        528                           0.00545                                0.32168
  **MCP4**             84                        19                          1663                        495                           0.00698                                0.41181
  **IL10**             3                         1                           179                         54                            0.00707                                0.41723
  **MIP3a**            18                        4                           1346                        414                           0.00784                                0.46274
  **IL6**              50                        5                           608                         184                           0.01139                                0.67211
  **VCAM1**            310701                    30008                       1278753                     336280                        0.01248                                0.73618
  **MMP3**             27613                     6960                        59390                       16227                         0.01433                                0.84561
  **KGF**              373                       117                         505                         109                           0.01473                                0.86914
  **ICAM1**            499363                    62669                       2313052                     682964                        0.01505                                0.88787
  **IL6R**             23556                     1882                        19437                       1316                          0.02143                                1.26450
  **IL4**              0                         0                           5                           2                             0.02359                                1.39181
  **IL8**              61                        4                           296                         90                            0.02410                                1.42202
  **IL18**             67                        11                          167                         43                            0.03041                                1.79442
  **IL16**             13                        6                           104                         43                            0.04344                                2.56278
  **MIP1a**            2952                      143                         3160                        156                           0.05446                                3.21343

Soluble Factors (pg/ml) present in the serum of patients undergoing high dose IL-2 immunotherapy were averaged before and after 4 doses of IL-2. A paired 2-tailed student *t*test was used to assess significance with an arbitrary cutoff of p = 0.05. Bonferroni\'s correction was applied to the data set by correcting for a total of 59 soluble factors (IL-2 was not factored in); IL-2 levels were included as internal control (\*) since these values reflect in part administered human recombinant IL-2.

###### 

Soluble factor (pg/ml) concentrations in the serum of 10 patients who completed the study (only factors that demonstrated significant changes in concentration between the 1^st^and 4^th^dose are shown)

  **Soluble Factor**   **Average before IL-2**   **STD error before Il-2**   **Average after 1 dose**   **STD error after 1 dose**   **Average after 4 doses**   **STD error after 4 doses**   **pvalue after 1 vs after 4 doses**   **Bonferroni correction**
  -------------------- ------------------------- --------------------------- -------------------------- ---------------------------- --------------------------- ----------------------------- ------------------------------------- ---------------------------
  **I309**             18                        4                           52                         8                            222                         25                            0.00004                               0.00232
  **MIP3b**            18                        4                           347                        51                           33836                       5140                          0.00007                               0.00414
  **TARC**             248                       59                          478                        112                          8993                        1517                          0.00015                               0.00882
  **E-Selectin**       106029                    5703                        118981                     5972                         377934                      40503                         0.00018                               0.01034
  **Exodus2**          419                       71                          307                        26                           1108                        157                           0.00028                               0.01628
  **MDC**              586                       111                         644                        109                          1272                        214                           0.00029                               0.01740
  **ITAC**             29                        4                           110                        26                           438                         57                            0.00033                               0.01935
  **Lymph**            111                       22                          259                        39                           639                         95                            0.00083                               0.04905
  **MCP3**             10                        1                           17                         2                            53                          8                             0.00101                               0.05956
  **TIMP1**            198383                    20136                       242215                     25530                        1021646                     178036                        0.00116                               0.06856
  **HGF**              8281                      2359                        10836                      1791                         17298                       1311                          0.00148                               0.08712
  **IL15**             0                         0                           6                          2                            14                          2                             0.00148                               0.08719
  **MMP13**            839                       221                         1081                       251                          1742                        171                           0.00163                               0.09604
  **MCP2**             32                        9                           1500                       291                          296                         34                            0.00174                               0.10287
  **MIP1b**            512                       205                         30149                      6560                         4072                        794                           0.00180                               0.10631
  **TNFR2**            3195                      259                         6014                       628                          16353                       3113                          0.00221                               0.13028
  **TNFa**             521                       65                          610                        59                           839                         74                            0.00281                               0.16587
  **MCP1**             984                       227                         81270                      13486                        31267                       4583                          0.00447                               0.26392
  **NAP2**             9479881                   2329514                     10970212                   2240959                      8251596                     2122243                       0.00482                               0.28444
  **IL5**              0                         0                           8                          2                            40                          10                            0.00564                               0.33291
  **MMP8**             1187                      455                         3340                       500                          5081                        927                           0.00852                               0.50244
  **MMP2**             210099                    37913                       201099                     41748                        399516                      50101                         0.00889                               0.52449
  **MCP4**             84                        19                          264                        71                           1663                        495                           0.00932                               0.54966
  **IL6R**             23556                     1882                        26254                      3045                         19437                       1316                          0.01011                               0.59636
  **ICAM1**            499363                    62669                       501688                     90740                        2313052                     682964                        0.01143                               0.67431
  **MMP3**             27613                     6960                        24603                      5418                         59390                       16227                         0.01149                               0.67778
  **MMP10**            1467                      220                         1694                       218                          3247                        528                           0.01209                               0.71314
  **TIMP2**            75277                     5629                        85674                      4973                         108359                      4266                          0.01334                               0.78706
  **VCAM1**            310701                    30008                       335385                     17713                        1278753                     336280                        0.01469                               0.86698
  **IP10**             146                       18                          1571                       273                          2940                        390                           0.01571                               0.92712
  **IL10**             3                         1                           45                         23                           179                         54                            0.02652                               1.56497
  **IL18**             67                        11                          93                         19                           167                         43                            0.03116                               1.83873
  **TNFR1**            1641                      112                         4702                       512                          6067                        651                           0.03126                               1.84407
  **IL16**             13                        6                           19                         11                           104                         43                            0.04434                               2.61591
  **Rantes**           40861                     10853                       56208                      8799                         34797                       6495                          0.04881                               2.87988

Soluble Factors levels were averaged across 10 patients after 1 and 4 doses of IL-2. A paired 2-tailed student *t*test was used to assess significance with an arbitrary cutoff of p= 0.05. Bonferroni\'s correction was applied to the data set by correcting for a total of 59 soluble factors.

We then classified the various factors according to their pattern of expression in response to IL-2 by applying unsupervised hierarchical clustering \[[@B21]\]. We limited this analysis to the 47 cytokines whose concentration levels were significantly altered after the 4^th^dose (Figure [1](#F1){ref-type="fig"}). Hierarchical clustering ranks experiments according to their proximity to each other taking into account the entire data set. This unsupervised analysis separated individual samples into three groups that matched the time of collection. In fact, samples obtained before treatment, those obtained after 1 dose and those after 4 grouped together with the exception of the sample obtained from patient 16 after the first dose that clustered with the pre-treatment samples. Analysis of the three categories of samples suggested that soluble factors in serum of patients treated with IL-2 belong to four categories according to their pattern of expression. A first category demonstrated a slight increase after the first dose and stabilized for the duration of the study (Black bar, Figure [1](#F1){ref-type="fig"}). A second group was characterized by an increase that occurred only after the fourth dose (Blue bar, Figure [1](#F1){ref-type="fig"}). A third group increased rapidly after one dose but concentrations decreased by the fourth dose (Orange bar, Figure [1](#F1){ref-type="fig"}). Finally, a last group increased in concentration after the first dose and progressively continued to increase after the 4^th^(Red bar, Figure [1](#F1){ref-type="fig"}).

![**Unsupervised Hierarchical clustering (Kendall\'s Tau) of serum samples from RCC patients obtained before, after 1 and 4 doses of IL-2 (720,000 IU/kg).**Hierarchical clustering \[21\] was applied to the data set encompassing 46 cytokines significantly expressed (excluding IL-2) between before and after 4 doses of IL-2 across 10 serum samples (P2,3,4,5,9,12,13,14,15,16) obtained before, after 1 and after 4 doses of IL-2 (720,000 IU/kg). Values corresponding to soluble factors concentration in pg/ml were transformed in natural log (LN) values, average corrected across experimental samples and displayed according to the central method for display using a normalization factor as recommended by Ross \[33\]. Patients\' serum samples clustered according to the three time points of IL-2 administration. Expression of soluble factors segregated in 4 distinct kinetic profiling. Black bar = soluble factor minimally changing from before to after 4 doses; blue bar = soluble factor expression enhanced at 4 doses only; orange bar = soluble factor expression enhanced after 1 dose; red bar = soluble factor expression enhanced at 1 and 4 doses.](1479-5876-2-17-1){#F1}

The majority of changes in the circulating soluble factors tested occurred after 4 doses of IL-2 (Blue bar Figure [1](#F1){ref-type="fig"} and Figure [2](#F2){ref-type="fig"}). In addition a large cluster of cytokines progressively increased from before therapy throughout IL-2 therapy (Figure [3](#F3){ref-type="fig"}). We observed several markers of systemic and vascular inflammation whose exact function *in vivo*remains to be elucidated (Figure [4](#F4){ref-type="fig"}). The soluble form of adhesion molecules ICAM1, V-CAM, E selectin have been reported to be similarly elevated in the serum of chronic renal allograft rejection patients \[[@B22]\], multiple sclerosis and Lupus ((\[[@B23],[@B24]\], coronary artery disease \[[@B25],[@B26]\], endothelial vasodilatation \[[@B27]\], immunotherapy of tumor patients with TNF alpha \[[@B28]\] and immunotherapy of melanoma patients with IL-12 \[[@B29]\] (Figure [5](#F5){ref-type="fig"}). Our findings may suggest similarly to these reports not only that circulating soluble adhesion molecules play a major role in the inflammatory reaction induced during IL-2 administration \[[@B12]\] but that they may be associated to the toxic effects of IL-2 (blood vessel inflammation, vascular damage, leakage, hypotension).

![**Soluble factors increasing after 4 doses of IL-2**Soluble factors increasing after 4 doses of IL-2 clustered in figure 1(blue bar), were averaged across 10 patients. Values represent concentrations in (pg/ml) ± SD.](1479-5876-2-17-2){#F2}

![**Soluble factors increasing after 1 and 4 doses of IL-2**Soluble factors increasing after 1 and 4 doses of IL-2 clustered in figure 1(red bar), were averaged across 10 patients. Values represent concentrations in (pg/ml) ± SD.](1479-5876-2-17-3){#F3}

![**Soluble Adhesion molecules in serum as markers of systemic and vascular inflammation: correlation with high dose IL-2 immunotherapy and other inflammatory diseases.**Increased levels of soluble adhesion molecules (sICAM, sVCAM, sV-Selectin, sTNFRI) and metalloproteinases (MMP2, MMP9) have been described in a variety of inflammatory diseases and believed to act as markers of endothelial cell (EC) activation. Potential explanation for IL-2 effects and toxicity in relation to the effects noted in the reported inflammatory diseases, are listed on the right of this panel.](1479-5876-2-17-4){#F4}

![**Soluble Adhesion molecules in serum as markers of systemic and vascular inflammation: correlation with high dose IL-2 immunotherapy and other therapies.**The presence of increased expression of soluble adhesion molecules (sICAM, sVCAM, sV-Selectin) detected in our study, have also been reported in the serum of patients undergoing TNF alpha and IL-12 immunotherapy. Furthermore, increased level of the inflammatory cytokines (IL-8, IL-6) and soluble TNF receptor (sTNFRI) confirmed previous findings in patients receiving high dose immunotherapy with IL-2.](1479-5876-2-17-5){#F5}

Metalloproteinases (MMP) 2, 3, 10, 13, tissue inhibitor of metalloproteinase (TIMP1), macrophage derived chemo-attractant (MDC) and thymus and activation regulated chemokine (TARC), Lymphotactin, secondary lymphoid tissue chemokine (Exodus2), and interferon inducible T cell alpha chemo-attractant (I-TAC) were also on average increased after 4 doses of IL-2. The presence of high levels of MMP is in line with the inflammatory process previously described by us at the genomic level \[[@B12]\] and general outburst of cytokines following IL-2 stimulation. In fact, MMP are involved in matrix destruction and regeneration, mononuclear phagocyte migration and function as regulatory proteins by promoting the activation and/or degradation of cytokines. High serum levels of MMP 2 and 9 have been reported in inflammatory diseases of the central nervous system and in particular in MS patients and play a leading role in the evolution of demyelinating lesions((\[[@B23]\]. We could thus hypothesize that the presence of high levels of circulating MMP following IL-2 therapy (after 1 and 4 doses) may be responsible for destruction of endothelial basement membranes, extravasation of mononuclear cells and more generally accumulation of toxic byproducts (Figure [4](#F4){ref-type="fig"}). In addition, it suggests a key involvement of mononuclear phagocytes activation in the IL-2-induced inflammatory process \[[@B12]\] since these cells are major producers of MMPs.

Interestingly, tissue inhibitor of metalloproteinase (TIMP1) was also highly expressed after 4 doses. Although the concomitant presence of MMP2 and TIMP1 is not surprising since TIMP1 is the natural inhibitor of MMP2 and MMP9 (which we find particularly increased after 1 and 4 doses), the concurrent dramatic increase of these two factors may reflect an inhibitory feed back mechanism limiting the magnitude of IL-2 induced inflammation. It is also possible that TIMP1 at such high doses may increase cell proliferation and metabolic activity as previously reported \[[@B30]\].

Elevated MDC and TARC, Lymphotactin, Exodus2 and I-TAC supports the presence of a strong migration signal for monocytes, NK cells and T cells as described by us at the RNA level \[[@B12]\] and of a potent mobilization of innate and acquired mechanisms of immune defense. Among the soluble factors that increased significantly after 1 dose and either remained elevated or increased further in concentration after 4 doses (Figure [1](#F1){ref-type="fig"} Red bar), were a group of potent inflammatory chemo-attractants for monocytes and lymphocytes (MCP-1, MIP-3, IP-10, I-309, stromal derived factor (SDF1)), eosinophils (eotaxin), the soluble TNF R1, the cytokines IL-6, 7 and 8.

The high concentrations of soluble TNFR1 in patients undergoing IL-2 therapy are very striking. Circulating levels of TNF-α and sTNFRI have been reported to be significantly increased in rheumatoid arthritis patients with amyloidosis as those without \[[@B31]\] (Figure [4](#F4){ref-type="fig"}) and after IL-2 therapy \[[@B34]\] (Figure [5](#F5){ref-type="fig"}). Thus this soluble receptor may be yet another important player in enhancing the overall IL-2 inflammatory process. The persistence/increase of these factors throughout the first 24 hours of IL-2 administration (1--4 doses) may suggest that these early response proteins are the true initiator of many of the IL-2 immune enhancing effects. On the other hand, sustained release/accumulation may be the results of soluble receptor saturation and the initiation of a cascade of toxic byproducts.

An additional finding was the identification of two sub-groups of patients who seemed to produce different amount of cytokines in response to IL-2; a smaller group (including patient 9, 13 and 16) appeared to produce less cytokines compared with other patients. This is a finding similar to what was previously noted in a small *in vitro*analysis of PBMC stimulated with IL-2 \[[@B15]\]. This finding if corroborated by larger patient series may have important implications in separating patients who respond or do not respond to therapy.

The number of patients tested was too small to correlate patterns of expression of various factors with the toxicity experienced or the clinical outcome of their treatment (data not shown).

In summary, this pilot study identified different patterns of production of cytokines during IL-2 therapy that may be of relevance to clinical outcome and toxicity if studied in larger patient populations. In addition, patients\' variability was noted with some patients appearing to be more prone to produce cytokines in response to IL-2. Immune polymorphism(s) affecting individual responses to immune stimulation could be at the basis of this phenomenon \[[@B32]\]. Therefore, further studies should include not only collection of serum samples for serum analysis but also of DNA for genetic analysis. Based on this analysis, we propose a prospective collection of serum samples in a larger cohort of patients undergoing IL-2 administration with the purpose of discerning patterns predictive of clinical outcome and toxicity.

Materials and Methods
=====================

Patients
--------

Sixteen patients with metastatic RCC were recruited at the Carolinas Medical Center (Charlotte, NC 28203) to receive standard high-dose (720,000 IU/Kg) IL-2 (Proleukin, Chiron, Emeryville, CA). Serum was collected prior to treatment from the 16 patients, three hours after the first dose in 15 patients and 3 hours after the first and the fourth dose in 10 patients (Table [1](#T1){ref-type="table"}). Toxicities and laboratory abnormalities are reported according to the CMC common toxicity criteria in Table [2](#T2){ref-type="table"}.

Serum collection
----------------

Fifty to 60 ml of peripheral blood were collected at the bedside in BD Vacutainer™ plus (plastic) serum tubes (BD cat \# 367820) before (Pre) and 3--4 hours after 1 (1D) and 4 (4D) doses of IL-2. The complete collection was successful in 10 individuals. Pre and 1D collections were obtained from an additional 5 patients. Serum was immediately separated to avoid protein degradation, stored upright for 10 minutes and centrifuged at room temperature in a horizontal rotor at 3,500 rpm for 8 minutes. The serum phase was then transferred to a 50 ml conical tube (BD, falcon \# 352098) pooling serum from 2 to 3 separator tubes and subsequently aliquoted (1 ml/vial) in cryogenic vials (Nunc cat \#363401, St Pleasant Prairie, WI). Serum aliquots were snap frozen in dry ice and stored at -80°C until use.

Protein platforms
-----------------

Protein serum levels were assessed on protein-based platforms (Pierce SearchLight Proteome Arrays, Boston, MA). These arrays consist of multiplexed assays that measure 16 or more proteins per well in standard 96 well plates. The arrays are produced by spotting a 2 × 2, 3 × 3 or 4 × 4 patterns of different monoclonal antibodies into each of a 96-well plate. Following a typical sandwich ELISA procedure, signal is generated using a chemiluminescent substrate. The light produced at each spot in the array is captured by imaging the entire plate with a commercially available cooled CCD camera. The data are reduced using image analysis software that calculates exact values (pg/ml) based on standard curves. Each sample was tested for the following 68 human proteins: monocyte inhibitory protein (MIP)-1α; MIP-1β; monocyte chemotactic protein (MCP)-1/CCL1; MCP-2/CCL8; MCP-3/CCL7; MCP-4/CCL13; macrophage inflammatory protein (MIP)-3β /CCL19; MIP-3α /CCL20; exodus2/CCL21(similar to MIP3α); thymus and activation regulated chemokine (TARC/CCL17); I-309/CCL1; eotaxin/CCL11; macrophage derived chemo-attractant (MDC/CCL22); interferon inducible protein 10 (IP10/CXCL10); stromal derived factor (SDF1)-beta; lymphotactin/XCL1; leukocyte Inhibitory factor (LIF); rantes/CCL5; monokine induced by gamma interferon (MIG/CXCL9); ITAC; TNFα; IFNγ; IFNa; GM-CSF; ENA-78/CXCL5; Gro-A/CXCL1; neutrophil activating protein (NAP)-2/CXCB7; vascular endothelial growth factor (VEGF); angiotensin (Angio)-2; ciliary neuronotrophic factor (CNTF); fibroblast growth factor (FGF)-basic; keratinocyte growth factor (KGF); hematopoietic growth factor (HGF); heparin binding epidermal growth factor (HB-EGF); platelet derived growth factor PDGF-BB; thymopoietin (Tpo); tissue inhibitor of metalloproteinases (TIMP)1; TIMP2; matrixmetalloproteinase (MMP)-1; MMP-2; MMP-3; MMP-8; MMP-9; MMP-10; MMP-13; interleukin (IL)-1α; IL-1β; IL-2; IL-4; IL-5; IL-6; IL-7; IL-8; IL-9; IL-10; IL-12p70; IL-13; IL-12p40; IL-15; IL-16; IL-18; tumor necrosis factor receptor (TNFR)-1; TNFR2, interleukin-6 receptor (IL-6R); ICAM1; VCAM1; E-Selectin/CD62E; L-Selectin/ CD62L.

Statistical analysis
--------------------

Eight of these factors (LIF, IFNα, GM-CSF, IL-1α, IL-1β, IL-9, IL-12p70, IL-13), were found to be below the limit of detection in all conditions tested and were removed from the data set prior to statistical analysis because we could not determine with certainty whether changes in their expression occurred below such a threshold. Paired two tailed *t*test was used to determine the level of significance in serum concentration changes for the remaining 60 soluble factors at different time points. IL-2 was included in the analysis as an internal control. Differences were considered significant at an arbitrary cut off p~2~-value of ≤ 0.05. Significance was also assessed after correction for the number of tests performed applying the Bonferroni\'s correction to 59 soluble factors (IL-2 was not considered among the tested variables since it was not possible to discern the respective contribution to serum concentration of exogenously administered or endogenously secreted IL-2).

Relatedness in cytokine expression patterns at different time points of IL-2 treatment was tested with unsupervised by applying Eisen\'s hierarchical clustering methods \[[@B21]\] to the data set encompassing the 45 cytokines and the 10 samples (P2,3,4,5,9,12,13,14,15,16, Figure [1](#F1){ref-type="fig"}). This tool ranks experiments according to their proximity to each other taking into account the entire data set.
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